Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading Down 3% – Here’s What Happened

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) shares fell 3% during trading on Tuesday . The company traded as low as $2.22 and last traded at $2.28. 11,568 shares were traded during trading, a decline of 6% from the average session volume of 12,338 shares. The stock had previously closed at $2.35.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Armata Pharmaceuticals in a research report on Thursday, August 15th.

Armata Pharmaceuticals Price Performance

The firm has a market cap of $82.49 million, a P/E ratio of -0.97 and a beta of 0.80.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.13). Research analysts anticipate that Armata Pharmaceuticals, Inc. will post -1.02 EPS for the current year.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.